Novo Nordisk is suing to block compounding pharmacies from producing cheaper versions of its medications, Ozempic and Wegovy. The company argues that the complex nature of these drugs makes them unsafe for replication and is urging the FDA to ban compounded alternatives due to health risks, amid ongoing shortages of semaglutide.
Tag: semaglutide
Swiss skincare company Galderma Group promises solution for ‘Ozempic Face’.